What is Obatala Sciences?
Obatala Sciences is a life sciences manufacturer specializing in human-derived hydrogels, stem cells, and functional Fat-on-a-chip models. Their technology is designed to provide deeper insights into metabolic diseases, thereby facilitating the crucial transition from research and development to clinical trials. The company's product portfolio includes various ObaCell kits, hydrogels, and media, complemented by specialized services in stem cells and biomaterials. Obatala Sciences aims to develop equitable and effective therapies globally by enhancing preclinical insights.
How much funding has Obatala Sciences raised?
Obatala Sciences has raised a total of $3.1M across 2 funding rounds:
Debt
$92K
Series A
$3M
Debt (2021): $92K with participation from PPP
Series A (2022): $3M led by Elevate Capital Fund, Ochsner Lafayette General Healthcare Innovation Fund, être Venture Capital, Benson Capital Partners, and Hackett Robertson Tobe Group
Key Investors in Obatala Sciences
Hackett Robertson Tobe Group
Hackett Robertson Tobe Group is an independent institutional investment consulting firm providing customized investment counsel. They specialize in wealth management, pension consulting, and impact investing, with a focus on equitable and sustainable solutions.
Benson Capital Partners
Benson Capital Partners operates within the Investment Banking industry, focusing on providing capital and advisory services. The firm is headquartered in New Orleans, Louisiana.
Elevate Capital Fund
Elevate Capital Fund is an investment entity participating in the Series A funding round for Obatala Sciences, indicating a focus on supporting growth-stage companies in the life sciences sector.
What's next for Obatala Sciences?
The recent major enterprise-level funding positions Obatala Sciences for significant expansion and further development of its proprietary technologies. This strategic investment is expected to accelerate the company's growth trajectory, enabling enhanced research capabilities and broader market penetration. The focus on improving preclinical drug development through advanced biomaterials and cell models suggests a continued commitment to innovation in addressing complex metabolic diseases and bringing novel therapies closer to patients.
See full Obatala Sciences company page
